Company profile
Bakhu Holdings, Corp.
OTC: BKUH · Healthcare · Drug Manufacturers - Specialty & Generic
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ 20GM —SS 24
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, listing tenure · ↓ workforce scale, return on assets
Methodology →Revenue TTM
-$233.4k
Rev growth YoY (TTM)
-200.0%
Net income (FY)
-$10.3M
Employees
2
as of 2026-08-27
Market cap
$301.3k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$10.3M-$10.3M2023
Operating income-$10.0M-$10.0M2023
Total assets$471.0k$471.0k2023
Liabilities$9.8M$9.8M2023
Equity-$9.3M-$9.3M2023
Revenue trend
FY2019 – FY2023 · USD
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bakhu Holdings, Corp.’s revenue?
Bakhu Holdings, Corp. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Actavia Life Sciences, Inc.——Biocure Technology Inc.——Marijuana Inc.——Planet Based Foods Global Inc.38DBio-Path Holdings, Inc.——Multicorp International, Inc.——Neighbors
Los Angeles →Key facts
CEOKonstantia Galazi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLong Beach, CA
ExchangeOTC: BKUH
Employees2
IPO date2018-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.